RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

Inclusion Criteria

• •1. Have prescription of Rituximab Pfizer or Rituxan within the enrollment period (Index Date: first prescription date within the enrollment period).
• •2. Have diagnosis of CD20 positive B-cell non- Hodgkin's lymphoma on the index month or within 6 months before index date
• •3. Have at least 6 months of Look back period and at least one medical record prior to 7 months before the Index date.
• •4. Have not prescription of Rituximab product before index date(Comparative Analysis Set only).